Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Lifted by American Century Companies Inc.

American Century Companies Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,051,517 shares of the biopharmaceutical company’s stock after buying an additional 288,009 shares during the quarter. American Century Companies Inc. owned 0.16% of Gilead Sciences worth $189,499,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. HHM Wealth Advisors LLC boosted its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences during the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the fourth quarter valued at about $29,000. Crews Bank & Trust bought a new position in Gilead Sciences during the fourth quarter valued at about $31,000. Finally, Stephens Consulting LLC boosted its stake in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.1 %

GILD opened at $107.08 on Friday. The business has a 50 day moving average price of $103.68 and a 200 day moving average price of $93.85. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market cap of $133.35 billion, a P/E ratio of 289.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is currently 854.05%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Bank of America increased their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Finally, Piper Sandler increased their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $104.52.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 in the last three months. Company insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.